The Latest Breaking News from CL

It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.

Colgate-Palmolive Company (NYSE:CL) is brushing up its future with a bold 2030 plan, even as it takes on up to $300M in restructuring charges.

Colgate-Palmolive is set to announce its second-quarter results early next month, with analysts expecting a modest single-digit decline in earnings.

Despite Colgate-Palmolive’s recent underperformance relative to its broader sector, analysts remain moderately optimistic about the stock’s prospects.

Colgate-Palmolive has significantly lagged behind the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Colgate-Palmolive is scheduled to report its first-quarter results this month, with analysts anticipating a single-digit growth in its bottom line.

Colgate-Palmolive has notably underperformed the Dow over the past year and analysts remain cautiously optimistic about the stock’s prospects.

Growing concerns over incoming tariffs and inflation are driving heightened uncertainty among U.S. consumers. As a defensive strategy, investors may find value in fundamentally stable consumer staples stocks like Procter & Gamble (PG), Coca-Cola (KO), and Colgate-Palmolive (CL). Continue to read….

Although Colgate-Palmolive has lagged behind the broader market over the past 52 weeks, Wall Street analysts remain moderately optimistic about the stock's prospects.

These consumer staples and wholesale companies represent a potential defense against market volatility heading into the new year.

Seaman Bailey Szramowski, 27, knew the pills were laced, but sold them to at least two shipmates anyway, according to federal investigators